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Abstract 
Introduction: It is unclear whether migraine with aura (MA) and migraine without aura (MO) 
are distinct subtypes or are genetically related. 
 
Aim: Using a novel gene-based (statistical) approach we aimed to identify individual genes 
and pathways associated with both MA and MO.  
 
Methods: Gene-based tests were performed utilizing genome-wide association summary 
statistics results from the most recent International Headache Genetics Consortium study 
comparing 4,505 MA cases with 34,813 controls and 4,038 MO cases with 40,294 controls. 
After accounting for non-independence of gene-based test results, we examined the 
significance of the proportion of shared genes associated with MA and MO. 
 
Results: We found a significant overlap in genes associated with MA and MO. Of the total 
1,514 genes with a nominally significant gene-based P-value (Pgene-based ≤ 0.05) in the MA 
subgroup, 107 also produced Pgene-based ≤ 0.05 in the MO subgroup. The proportion of 
overlapping genes is almost double the empirically derived null expectation, producing 
significant evidence of gene-based overlap (Pbinomial-test = 1.6×10-3). Combining results across 
MA and MO, six genes produced genome-wide significant gene-based P-values. Four of 
these genes (TRPM8, UFL1, FHL5 and LRP1) were located in close proximity to previously 
reported genome-wide significant SNPs for migraine; while two genes, TARBP2 and NPFF 
closely located on chromosome 12q13.13, represent novel candidate risk genes. The genes 
overlapping in both migraine types were enriched for functions involved in inflammation, 
cardiovasculature and connective tissue. 
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Conclusions: Our results provide novel insight into the likely genes and biological 
mechanisms that underlie both MA and MO, and when combined with previous data, 
highlight NPFF as novel candidate risk genes for both types of migraine. 
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Introduction 
Two common forms of migraine exist that are clinically distinguished by the presence of aura 
symptoms prior to the headache phase and hence are called migraine with aura (MA) and 
migraine without aura (MO) (1). The migraine aura is caused by cortical spreading 
depression (CSD), a slowly self-propagating wave of neuronal and glial depolarization in the 
cortex (2). The headache is caused by activation of the trigeminovascular system, which leads 
to abnormal processing of pain signals in the brain stem and subsequent activation of higher 
order brain centres giving the sensation of pain (3). CSD has been shown to activate this pain 
pathway in experimental animal studies, although such proof is essentially lacking in patients 
(4) . Whereas the biological mechanisms in the early phase of an attack seem to differ 
between MA and MO, they may be similar in the headache phase. Supportive evidence for 
converging headache generating mechanisms in both migraine types comes from the fact that 
some drugs have equal efficacy in treating both types of migraines (5). Moreover, several 
studies have reported that MA and MO frequently coexist within the same family (6, 7). A 
large population-based study has reported high co-occurrence of MA and MO, and found that 
13% of patients have both MA and MO, which is higher than expected from their individual 
prevalence (8). Thus, the frequent co-occurrence of the two disorders within families and 
individuals suggest MA and MO share―at least to some extent―the same biological 
mechanisms. In support of this idea, latent class and genetic analysis of migraine symptom 
data in large Australian (9) and Dutch (10) twin samples indicated the existence of a 
continuum of severity, with MA being more severe but not etiologically distinct from MO. 
 
Genetics studies are starting to discover genes and loci associated with migraine. A recent 
genome-wide association (GWA) meta-analysis of 23,285 migraine cases and 95,425 controls 
of European ancestry that was conducted by the International Headache Genetics Consortium 
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(IHGC) identified 142 single nucleotide polymorphisms (SNPs) at 12 independent loci 
significantly associated with migraine (P-values  < 5×10-8) (11). Many genes in or near these 
loci are involved in neuronal function, thus supporting a role for neuronal signaling in 
migraine etiology as had previously been shown for monogenic familial hemiplegic migraine, 
a subtype of migraine with aura (12). In addition, 1,168 SNPs at 134 loci showed suggestive 
association with migraine (P-values < 1×10-5) (11). When considering only the genome-wide 
significant hits, GWA studies have been most successful utilizing case samples satisfying 
criteria for only MO, with six loci identified (11, 13) compared to only one locus utilizing 
case samples satisfying criteria for only MA (14). The remaining five genome-wide 
significant loci were identified by studying case samples satisfying MA and/or MO (11). A 
lack of detailed clinical data precluded a more in-depth analysis of migraine subtypes. 
 
We previously compared the effects (odds ratios, OR) of the top SNPs from the 12 genome-
wide significant loci in the only MA and only MO subgroups, and showed that four SNPs 
(rs10915437, rs9349379, rs13208321, rs10504861) had a heterogeneous effect size (P-value 
= 4.4×10-3, 3.2×10-4, 4.9×10-2, 4.5×10-3, respectively). However, for all 12 SNPs, the risk-
increasing allele was the same across these subgroups and an analysis of ~23,000 
independent SNPs found the majority of genome-wide SNP effects to be in the same 
direction across the MA and MO subgroups (15). 
 
To more thoroughly assess the genetic overlap between MA and MO (i.e., beyond inspection 
of the genome-wide significant loci and individual SNP effects), we performed gene-based 
tests of association using GWA data for MA and MO from the IHGC meta-analysis. We 
evaluated the gene-level genetic relationship between MA and MO by testing whether the 
number of overlapping genes―i.e., genes with nominally significant gene-based association 
9	
	
P-values for both MA and MO―was more than expected by chance. The overlapping genes 
were also utilized in pathway and network analyses, to identify potential canonical pathways, 
biological functions, and molecular networks underlying both migraine with and without 
aura.  
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Methods 
GWA data 
GWA summary statistic results for MA and MO were obtained from the 2013 IHGC GWA 
meta-analysis (11). Of the 18 total GWA studies comprising the original GWA meta-analysis, 
summary statistics from 7 studies with case samples satisfying criteria for only MA, and 4 
studies with case samples satisfying criteria for only MO were utilized (Table S1). The 
selected MA (total 4,505 MA cases versus 34,813 controls) and MO (total 4,038 MO cases 
versus 40,294 controls) studies do not contain overlapping individuals and are of similar total 
size. 
 
Genome-wide SNP genotyping was performed independently in each cohort with the use of 
various standard genotyping technologies, and imputed for each study with reference to 
HapMap release 21 or 22 CEU-phased genotypes. Each study contributed summary statistic 
data from an association analysis performed using a frequentist additive model based on 
estimated SNP allelic dosages, adjusting for gender. SNPs were filtered on a per-study level 
based on inclusion criteria of minor allele frequency (MAF) > 0.1% and imputation quality 
measures of IA > 0.6 (IMPUTE 2) or r2 > 0.3 (MaCH). The 1,680,313 ‘consensus’ SNPs 
analyzed in the original IHGC GWA meta-analysis (11) were utilized in the present study. 
GWA summary statistic results for the 7 MA studies were meta-analyzed in a fixed-effect 
model using GWAMA (16). GWA summary statistic results for the 4 MO studies were 
analogously meta-analyzed using GWAMA	(16). The resulting MA and MO GWA meta-
analysis results were subsequently utilized in gene-based tests for association. 
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Gene-based association test 
We obtained RefSeq gene information (hg19) from UCSC genome browser [download 
20/03/14]. Overlapping isoforms of the same gene were combined to form a single full length 
version of the gene. Isoforms that didn't overlap were left as duplicates of that gene. For the 
duplicated genes, the gene with the lowest downstream gene-based P-value was retained. 
This led to 24,383 unique genes. The IHGC SNP positions were converted from hg18 to hg19 
using the liftOver utility (https://genome.ucsc.edu/cgi-bin/hgLiftOver), and were assigned to 
genes if they mapped to between 15 kb 5’ of the transcription start site (TSS) and 15 kb 3’ of 
the transcription end site (TES). The 15-kb gene boundary extension was chosen based on the 
observation that 90% of SNPs effecting expression quantitative trait loci (eQTLs) were 
within this proximity (17). Gene-based association tests were performed using the GATES 
test (18) implemented in the Fast ASsociation Tests (FAST) package (19). GATES performs 
the gene-based test by adjusting the observed P-value of the most significant SNP located in 
a gene, by the effective number of independent SNPs tested across the gene.  
 
Given the possibility that gene-based results of neighboring genes may in fact be correlated 
because the most significant SNPs are the same or in strong linkage disequilibrium (LD), we 
estimated the effective number of independent genes (gene-based tests) by examining the LD 
between the most significant SNPs within each gene. This calculation was performed using 
the Genetic type I Error Calculator (GEC) (20). GEC is a method addressing the multiple-
testing issue with dependent SNPs. In short, GEC first divides the input SNPs into LD 
blocks, and assumes LD blocks as independent (r2 < 0.1), then by examining the eigenvalues 
obtained from spectral decomposition of the LD correlation matrix of SNPs, GEC estimates 
the effective number of independent SNPs in the blocks.  
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Overlapping genes and statistic tests 
After the gene-based test, we generated gene sets with gene-based association P-values less 
than three nominally significant thresholds (P-values < 0.01, < 0.05, or < 0.1) in the MA and 
MO datasets. For each gene set, the effective number of independent genes was calculated. 
Subsequently, we regarded the MA dataset as the ‘discovery’ set and the MO dataset as the 
‘target’ set to test whether the proportion of overlapping genes between MA and MO for each 
of the thresholds is more than expected by chance. Here, the observed number of overlapping 
genes is defined as the effective number of genes with P-values less than the threshold in 
both the discovery (MA) and target (MO) sets. The observed proportion of overlapping genes 
is the observed effective number of overlapping genes divided by the effective number of 
genes with a P-value less than the threshold in the discovery set. The expected proportion of 
overlapping genes is the effective number of genes with a P-value less than the threshold in 
the target set divided by the total effective number of genes in the target set. The statistical 
significance of whether the number of overlapping genes was more than expected by chance 
was calculated using exact binomial statistical tests. 
 
Pathway analysis 
The pathway analysis was designed to discover biological mechanisms that are shared 
between MA and MO. Here, we used Ingenuity Pathway Analysis (IPA) software, which is 
widely used to identify pathways enriched in a gene-set based on biological interactions and 
functional annotations (21, 22). The significance of the identified pathways was evaluated by 
Fisher’s exact statistical test. The pathway data sources include “Canonical pathways”, 
“Biological Functions”, and “Networks”. “Canonical pathways” contain well-characterized 
metabolic and cell signaling pathways from specific journal articles, review articles, text 
books, and KEGG LIGAND. “Biological functions” are used to explore the enriched 
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functions and annotated diseases of input genes. “Networks” represent diagrams of known 
protein-protein interactions, and are generated based on the input data.   
 
We performed the IPA analysis utilizing genes with a P-value < 0.1 in both the MA and MO 
GWA datasets. The results can potentially be biased due to non-independent (neighboring) 
genes. For example, one pathway may include multiple genes tagged with the same top SNP 
or SNPs that are in strong LD. We, therefore, checked the IPA results to ensure such bias did 
not contribute to the identified associated pathways.  
 
Given that significant canonical pathways or biological functions may include redundant 
genes and gene-gene interactions, we explored their relationships by constructing customized 
networks. First, the genes overlapping between MA and MO were input into IPA. 
Subsequently, the focus genes (i.e., the subset of overlapping genes) involved in the 
significant canonical pathways/biological functions were again input into IPA but now to 
build functional networks for the significant canonical pathways/biological functions. As per 
IPA recommendations, biological functions were defined as significant if their P-values were 
< 0.01, and canonical pathways were considered significant if their P-values were < 0.05.  
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Results 
Effective number of genes for migraine with aura and migraine without aura 
For both MA and MO, we estimated the effective number of genes by inputting the most 
significant SNPs of all genes in our GEC analysis. Since we assigned the SNPs to genes, the 
total raw numbers of genes (21,116) are the same for the MA and MO datasets (Table 1). The 
slight difference in the effective number of total genes in the MA dataset (14,395) versus the 
MO dataset (14,485) results from differences in LD structure between the respective sets of 
most significant SNPs in each gene.  
 
Gene-level genetic relationships of migraine with aura and migraine without aura 
As shown in Table 2, significant overlaps were observed for genes with P-values <0.05 or 
<0.1 in both MA and MO, which indicates that a significant gene-level genetic relationship 
exists between MA and MO. Since the observed effective number of genes was higher than 
expected, we assumed that these genes have an increased probability to be truly associated 
with both disorders.  
 
Combined gene-based association across migraine with aura and migraine without aura 
Given the observed gene-based genetic overlap, we combined the evidence of gene-based 
association across MA and MO using the Fishers’ combined P-value method. As the effective 
number of independent gene-based tests ranged from 14,395 (MA) to 14,485 (MO), a gene-
based P-value < 3.45×10-6 (i.e., 0.05/14,485) is required to retain a Type I error rate of 5% 
and represent genome-wide significant association. Using this threshold value, six genes 
(TRPM8, UFL1, FHL5, TARBP2, NPFF and LRP1) were defined as genome-wide 
significantly associated with migraine (Table 3). The top significant SNPs for UFL1 and 
FHL5 on chromosome 6q16.1 are in strong LD, and the neighboring genes NPFF and 
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TARBP2 on chromosome 12q13.13 have the same top SNP (rs11170566), hence the most 
likely causative risk gene at these loci cannot be determined from the gene-based association 
results alone. Compared to results from the original migraine GWA meta-analysis of all 18 
studies (11), in addition to implicating four genes in close proximity to three previously 
reported genome-wide significant SNPs (TRPM8 near rs7577262 on 2q37.1; UFL1 and FHL5 
near rs13208321 on 6q16.1; and LRP1 near rs11172113 on 12q13.3), this study identified 
two candidate migraine risk genes (NPFF and TARBP2) at a locus on chromosome 12q13.13, 
which was not previously implicated in the GWA meta-analysis of all 23,285 migraine cases 
and 95,425 controls (11).  
 
Pathway analysis on overlapping genes 
The significant biological functions, canonical pathways, and networks found in the overlap 
between MA and MO are shown in Tables S2-S4. The most significant biological function is 
“chronic inflammatory disorder” (Table 4). Notably, two genes linked to the function 
“chronic inflammatory disorder”: TRPM8 (2q37.1) and UFL1 (6q16.1) have Fisher’s 
combined gene-based P-values surpassing the genome-wide threshold (3.45×10-6). The most 
significant canonical pathway is “Notch Signaling” (Table 4), which plays important roles in 
neuronal function and development (23-26). The most significant network is “Cardiovascular 
Disease, Organismal Injury and Abnormalities, Cardiac Stenosis” (Table 4). Other biological 
functions and networks that were significantly enriched in the overlap between MA and MO 
were mostly involved in cardiovascular, inflammation, development and connective tissue 
related functions (Tables S3-S4).  
 
As shown in Tables S2-S3, several significant biological functions and canonical pathways 
share the same candidate genes, which indicate that these functions are related. In order to 
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find the relationship between them, we constructed networks by IPA (described in Methods). 
The significant canonical pathways and biological functions were combined into five 
networks without overlapping genes (Table 5). 
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Discussion 
This study identified a significant gene-level genetic relationship between MA and MO by 
integrating gene-based tests and estimating the effective number of genes using the	GWA 
summary statistic results for both disorders from the recent meta-analysis conducted by the 
IHGC (11). Our approach is different from single-SNP-based approaches, e.g., polygenic 
prediction (27) and SNP effect concordance analysis (SECA) (28) which previously showed a 
significant SNP-based genetic overlap between MA and MO (15), as it has the ability to 
identify genes across disorders in the presence of allelic heterogeneity. The latter is of great 
importance as only 12 out of 271 genes with gene-based P-values < 0.1 for both MA and MO 
were shown to be tagged by the same top significant SNP. The other advantage of our gene-
based approach comes from the fact that genes are the predominant functional unit of the 
human genome and are therefore more closely related to biology mechanisms. 
 
From the combined analysis of MA and MO gene-based P-values, six genes surpass our 
genome-wide significance threshold: TRPM8, UFL1, FHL5, TARBP2, NPFF and LRP1 on 
chromosome 2q37.1, 6q16.1, 6q16.1, 12q13.13, 12q13.13 and 12q13.3, respectively. These 
results support the utility of our gene-based approach, especially given they are based on 
14,742 fewer migraine cases and 20,318 fewer controls (~41% smaller effective sample size) 
compared to the original IHGC GWAS of 23,285 migraine cases and 95,425 controls. Four of 
these genes (TRPM8, UFL1, FHL5 and LRP1) were located in close proximity to previously 
reported genome-wide significant SNPs, while two genes, TARBP2 and NPFF, represent 
novel candidate risk genes for migraine.  
 
The known molecular functions of TARBP2, TAR (HIV-1) RNA binding protein 2, that is 
encoded by the TARBP2 gene, centers on its requirement for formation of the RNA-induced 
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silencing complex. TARBP2 binds between the bulge and the loop of the HIV-1 TAR RNA 
regulatory element and activates HIV-1 gene expression in synergy with the viral Tat protein. 
TARBP2 is also an integral component of the DICER1-containing complex and involved in 
miRNA processing (29). Together with the gene ontology (GO) molecular function terms 
assigned to TARBP2 (double-stranded RNA binding, protein binding, siRNA binding, miRNA 
binding, and protein homodimerization activity), there is no obvious functional link between 
TARBP2 and migraine risk.  
 
The neuropeptide FF-amide peptide precursor (NPFF), encoded by the NPFF gene, has wide-
ranging physiologic effects, including the modulation of morphine-induced analgesia, 
elevation of arterial blood pressure, and increased somatostatin secretion from the pancreas. 
The GO molecular functions assigned to NPFF are G-protein coupled receptor binding, 
receptor binding, and neuropeptide hormone activity. Notably, neuropeptide FF potentiates 
and sensitizes acid-sensing ion channels ASIC1 and ASIC3. The ASICs represent proton-
gated channels that are able to flux Na+ and Ca2+. A recent study using whole-cell patch-
clamp electrophysiology showed that a decrease in extracellular pH can directly excite 
primary dural-afferent neurons via the opening of ASICs and produce migraine-related pain 
behavior, suggesting ASIC inhibitors may represent novel candidates for migraine therapy 
(30). Indeed, the ASIC inhibitor amiloride was recently shown to block cortical spreading 
depression (CSD)―the neurophysiological correlate of migraine aura―and inhibited 
trigeminal activation in in vivo in animals, via an ASIC1 mechanism (31). These previous 
findings suggest that NPFF is the most probable migraine risk gene on 12q13.13. 
 
To gain better understanding of the biological mechanisms that are involved in the two 
migraine subtypes, we also performed pathway analyses on the genes that showed nominal 
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association with both MA and MO. Pathway analysis based on biological functions provided 
22 significant diseases/functions (Table S2). Among them, many were related to 
inflammatory disorders. A causal role for inflammation in migraine pathophysiology has 
been described previously, as CSD can activate an inflammatory cascade that can reach the 
meninges  (32) where it may cause neurogenic inflammation and subsequent activation of 
trigeminal neurons and thereby activation of the migraine headache (32, 33).  
 
Gene functions and networks related to cardiovascular and connective tissue disorders 
showed enrichment in the overlap between MA and MO as well (Tables 5, S1 and S3). A 
possible role for the cardiovascular system in migraine has been suggested by the high 
coincidence of migraine with stroke and several cardiac disorders (34). The high coincidence 
was also observed on migraine with aura in cerebral autosomal dominant arteriopathy with 
subcortical infarcts and leukoencephalopathy (CADASIL) (35), which is caused by specific 
missense mutations in the NOTCH3 gene (36). Receptor NOTCH3 plays important roles in 
Notch signaling pathway. Interestingly, Notch signaling was indicated as one of the enriched 
pathways in the overlapping genes between MA and MO (Table 4). Although NOTCH3 was 
not indicated significantly associated with MA or MO in this study nor in any of the previous 
large migraine GWA studies (11, 13, 14, 37), candidate gene association studies have 
provided some genetic support for the relationship between NOTCH3 and migraine (38, 39).  
 
In summary, these results show a significant gene-based overlap between the primary 
subtypes MA and MO, further explaining―at least partly―their co-occurrence within the 
same patient or family. Our results also highlight four genes (TRPM8, UFL1, FHL5 and 
LRP1) that had earlier surfaced in GWA studies and two novel genes (TARBP2 and NPFF) as  
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candidate risk genes for migraine, and indicate that inflammatory and cardiovascular 
processes may be involved in the etiology of both MA and MO.  
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Article highlights 
• A significant overlap in associated genes exists between the primary subtypes MA and 
MO, further explaining―at least partly―their co-occurrence within the same patient or 
family.  
• Combining gene-based association results across MA and MO confirmed association of 
four genes at three previously implicated loci, and when combined with previous data, 
highlight NPFF as novel candidate risk genes for both types of migraine. 
• Results from pathway analyses indicate that inflammatory and cardiovascular processes 
may be involved in the etiology of both MA and MO. 
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